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Abstract
Osteosarcoma (OS) is the most common form of malignant bone tumor and is an aggressive malignant neoplasm exhibiting
osteoblastic differentiation. Cisplatin is one of the most efficacious antitumor drugs for osteosarcoma patients. However,
treatment failures are common due to the development of chemoresistance. CCN2 (also known as CTGF), is a secreted
protein that binds to integrins, modulates the invasive behavior of certain human cancer cells. However, the effect of CCN2
in cisplatin-mediated chemotherapy is still unknown. Here, we found that CCN2 was upregulated in human osteosarcoma
cells after treatment with cisplatin. Moreover, overexpression of CCN2 increased the resistance to cisplatin-mediated cell
apoptosis. In contrast, reduction of CCN2 by CCN2 shRNA promoted the chemotherapeutic effect of cisplatin. We also found
that CCN2 provided resistance to cisplatin-induced apoptosis through upregulation of Bcl-xL and survivin. Knockdown of
Bcl-xL or survivin removed the CCN2-mediated resistance to apoptosis induced by cisplatin. On the other hand, CCN2 also
promoted FAK, MEK, and ERK survival signaling pathways to enhance tumor survival during cisplatin treatment. In a mouse
xenograft model, overexpression of CCN2 promoted resistance to cisplatin. However, knockdown of CCN2 increased the
therapeutic effect of cisplatin. Therefore, our data suggest that CCN2 might be a critical oncogene of human osteosarcoma
for cisplatin-resistance and supported osteosarcoma cell growth in vivo and in vitro.
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Introduction
Osteosarcoma is the most common form of malignant bone
tumor and is also the eighth most common form of childhood
cancer. In pediatric patients, approximately 20% of all primary
bone cancers constitute 2.4% of all malignancies. Osteosarcoma
arises from mesenchymal cells and is pathologically characterized
by spindle cells and aberrant osteoid formation. The incidence of
osteosarcoma has a bimodal distribution in adolescence and in the
seventh and eighth decade of life. Cisplatin is one of the most
effective drugs against osteosarcoma [1]. However, in the past few
years, increasing chemoresistance has led to a decrease in the
number of osteosarcoma patients who improve [2]. Thus, the
analysis of the molecular mechanisms involved in the chemore-
sistance of osteosarcoma cells is pivotal to improving patient
survival.
There are 6 CCN family members, including CCN1 (cysteine-
rich protein 61, Cyr61), CCN2 (connective tissue growth factor,
CTGF), CCN3 (nephroblastoma overexpressed gene, Nov),
CCN4 (Wnt-1-induced secreted protein 1, WISP-1), CCN5
(WISP-2), and CCN6 (WISP-3) [3]. The biological properties of
CCN proteins include stimulation of cellular migration, adhesion,
proliferation, extracellular matrix (ECM) formation, and regula-
tion of tumorigenesis [4]. Many studies have confirmed that
CCN2 has a higher level of expression in lung cancer [5],
pancreatic cancer [6], breast cancer [7], chondrosarcoma [8], and
melanomas [9] than in normal tissues. Overexpression of CCN2 in
tumor cells has also been linked to increased tumor size and lymph
node metastasis [10]. Previous studies have demonstrated that
CCN2 expression confers resistance to chemotherapeutic agents in
glioblastoma [11] and ovarian cancer [12]. In chondrosarcoma
patients, the expression of CCN2 also correlates with the patient
survival ratio [13]. Therefore, these data suggest that CCN2
expression may be involved in the progression and chemoresis-
tance of human cancers.
CCN2 interacts with integrin to regulate a number of biological
functions [14]. It is commonly believed that survival of adherent
cells require signal transduction from the interactions between
integrins and the extracellular matrix (ECM). Such signals are in
turn transmitted to the cytoplasm by components of the focal
adhesions, in which focal adhesion kinase (FAK) is a considerable
player. The major site of FAK autophosphorylation, Tyr397, is
important for the biochemical and biological functions of FAK
[15]. On the other hand, FAK-dependent MEK/ERK activation
regulates expression of many functional genes that affect cell
survival, proliferation, and differentiation [16]. ERK1/2 also has
profound effects on the regulation of apoptosis by regulating the
phosphorylation of apoptotic regulatory molecules, including Bad,
Bim, Mcl-1, caspase-9, and Bcl-2 [17]. The hyperactivation of
ERK has been shown to promote resistance to chemotherapy
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drugs in many cancer cells [17,18]. Furthermore, survivin is a
member of the inhibitor of apoptosis (IAP) family. Strong survivin
expression is observed in the vast majority of cancers [19]. The
survivin protein can inhibit cell apoptosis or programmed cell
death through inhibiting functional caspase activation [20].
However, the signaling pathways in CCN2-mediated chemoresis-
tance in human osteosarcoma are mostly unclear and largely
unknown.
Although the role of CCN2 in chemoresistance has been
implicated in some cancer cells, the effect of CCN2 on cisplatin-
induced cell apoptosis in human osteosarcoma has not been
extensively studied. In this study, we found that CCN2 enhanced
resistance to cisplatin-increasing cell death in human osteosarcoma
in vivo and in vitro. Our results provide evidence that CCN2 might
be a novel chemotherapy target in human osteosarcoma cells.
Materials and Methods
Materials
Anti-rabbit and anti-mouse IgG-conjugated horseradish perox-
idase, rabbit polyclonal antibodies (specific for FAK, p-MEK,
MEK, p-ERK, and ERK), mouse monoclonal antibodies (specific
for CCN2, Bcl-xL, surviving, poly[ADP-ribose] polymerase
[PARP], and a-tubulin), and small interfering RNAs (siRNAs)
against Bcl-xL, survivin, and control (for experiments using
targeted siRNA transfection; each consists of a scrambled
sequence that will not lead to the specific degradation of any
known cellular mRNA) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal
antibody specific for p-FAK was purchased from Cell Signaling
and Neuroscience (Danvers, MA, USA). MEK inhibitors
(PD98059 and U0126) were purchased from Calbiochem (San
Diego, CA, USA). The phosphorylation site mutant of FAK(Y397F)
was a gift from Dr. J. A. Girault (Institut du Fer a` Moulin, Moulin,
France). The MEK1 dominant-negative mutant was provided by
Dr. W. M. Fu (National Taiwan University, Taipei, Taiwan). The
ERK2 (K52R) dominant-negative mutant was a gift from Dr. M.
Cobb (University of Texax, Dallas, TX). All other chemicals were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
The human osteosarcoma cell lines (MG-63, U-2 OS, and
HOS), human lung adenocarcinoma cell lines (A549), human
prostate cancer cell lines (PC3), and human gastric adenocarcino-
ma epithelial cell line (AGS) were purchased from the American
Type Cell Culture Collection (Manassas, VA, USA). MG-63 and
HOS cells were maintained in Eagle’s Minimum Essential
Medium. A549 and AGS cells were maintained in Nutrient
Mixture Ham’s F12 medium. PC3 cells were maintained in
Roswell Park Memorial Institute (RPMI) 1640 medium. All the
mediums were supplemented with 20 mM HEPES and 10% heat-
inactivated FCS, 2 mM glutamine, penicillin (100 U/ml), and
streptomycin (100 mg/ml) at 37uC with 5% CO2. U-2 OS cells
were maintained in McCoy’s 5A medium, which was supple-
mented with 10% FBS, penicillin (100 U/ml), and streptomycin
(100 mg/ml) at 37uC with 5% CO2.
Overexpression of CCN2 with the pcDNA3.1- CCN2
expression vector
The complete CCN2 open reading frame was amplified by
reverse transcription (RT)-PCR. Subsequent PCR amplification
from RT reaction products was performed in 0.2 mM dNTPs,
1.5 mM MgCl2, 40 U/ml of PlatinumH Pfx DNA Polymerase
(Invitrogen, Groningen, The Netherlands), and 1 nmol of each
PCR primer, designed to amplify the full-length CCN2 cDNA
(sense: CCAACCATGACCGCCGCCAG, and antisense:
TCATGCCATGTCTCCGTACATCTTCCTG). PCR products
were purified from agarose gels using the Viogene Gel/PCR DNA
Isolation System (Viogene, CA, USA). The complete CCN2 was
cloned into the topoisomerase-activated pcDNA3.1-TOPO vector
(Invitrogen).
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
Cell viability was determined by the MTT assay. Cells were
plated in 96-well plates at a concentration of 2,000 cells per well.
After treatment with cisplatin or doxorubicin for 24 h, cultures
were washed with PBS [21]. Next, 0.5 mg/ml of MTT solution
was added to each well and incubated at 37uC for 30 min. To
dissolve formazan crystals, culture medium was replaced with an
equal volume of DMSO. After the mixture was shaken at room
temperature for 10 min, absorbance of each well was determined
at 550 nm using a microplate reader (Bio-Tek, Winooski, VT,
USA).
Colony formation assay
Cells were plated in 12-well plates at a concentration of 16104
cells per well. After treatment with cisplatin for 48 h, cells were
washed with PBS and replaced with fresh medium. Cells were
allowed to form colonies for 7 days before being stained with
crystal violet (0.4 mg/ml). After washing 3 times with PBS, acetic
acid was added to a final concentration of 33% (v/v), and the
absorbance was measured at 550 nm.
Quantification of apoptosis by flow cytometry
Quantitative assessment of apoptotic cells was assessed by
examining the cell cycle. Cells were collected by centrifugation
and adjusted to 36106 cells/ml. Pre-chilled ethanol was added to
0.5-ml cell suspensions, and the mixture was incubated at 4uC for
30 min. Ethanol was removed by centrifugation, and cellular
DNA was stained with 100 mg/ml propidium iodide (PI; in PBS
containing 0.1% Triton-X 100, and 1 mM EDTA) in the presence
of an equal volume of DNase-free RNase (200 mg/ml). After
staining, cells were analyzed immediately with a FACScan and
Cellquest program. The extent of apoptosis was determined by
measuring the DNA content of cells below the sub-G1 peak.
A terminal deoxynucleotidyl transferase-mediated deoxyuridine
triphosphate nick end labeling (TUNEL) assay was also used to
examine cell apoptosis using the BD ApoAlertTM DNA Fragmen-
tation Assay Kit (BD Biosciences, California, USA). Cells were
incubated with cisplatin for 24 h, trypsinized, fixed with 4%
paraformaldehyde, and permeabilized with 0.1% Triton-X-100 in
0.1% sodium citrate. After being washed with PBS, the cells were
incubated with the reaction mixture for 60 min at 37uC. The
stained cells were then analyzed with a flow cytometer.
49-6-diamidino-2-phenylindole (DAPI) staining
Apoptotic nuclei were detected using DAPI staining. Cells were
plated in 6-well plates at a concentration of 16106 cells per well.
After being treated with cisplatin at various concentrations for
48 h, cells were washed with PBS, fixed with 4% paraformalde-
hyde, and analyzed via fluorescence microscopy to assess
chromatin condensation and segregation.
Caspase-3 activity assay
Caspase-3 activity was measured by the direct assay of caspase-3
enzyme activity in cell lysates using synthetic chromogenic
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substrate (Ac-DEVD-pNA; substrate for caspase-3). Cell lysates
were prepared and incubated with anti-caspase-3. Immunocom-
plexes were incubated with peptide substrate in assay buffer
(100 mM NaCl, 50 mM 4-(2-hydroxyethyl)-1-piperazine-ethane-
sulphonic acid [HEPES], 10 mM dithiothreitol, 1 mM EDTA,
10% glycerol, and 0.1% 3-[(3-cholamidopropyl) dimethylammo-
nio]-1-propanesulfonate [CHAPS], pH 7.4) for 2 h at 37uC. The
release of p-nitroaniline was monitored at 405 nm. Results are the
percent change in activity compared to an untreated control.
Western blotting analysis
The cellular lysates were prepared as described previously [22].
Protein concentration was determined using the Thermo Scientific
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific Inc.,
Waltham, MA). Proteins were resolved on SDS-PAGE and
transferred to immobilon polyvinyldifluoride (PVDF) membranes.
The blots were blocked with 4% BSA for 1 h at room temperature
and incubated with the following primary antibodies for 1 h at
room temperature to detect antigen: mouse monoclonal anti-
CCN2, Bcl-xL, survivin, or a-tubulin (Santa Cruz Biotechnology)
or rabbit polyclonal anti-FAK, p-MEK, MEK, p-ERK, or ERK
(Santa Cruz Biotechnology). After 3 washes in tris-buffered saline
with 0.05% Tween 20 (TBS-Tween), the blots were subsequently
incubated with a donkey anti-rabbit or anti-mouse peroxidase-
conjugated secondary antibody for 1 h at room temperature. The
blots were visualized by enhanced chemiluminescence using
Kodak X-OMAT LS film (Eastman Kodak, Rochester, NY).
Quantitative data were obtained using a computing densitometer
and ImageQuant software (Molecular Dynamics, Sunnyvale, CA).
Quantitative real-time PCR
Total RNA was extracted from osteosarcoma cells using a
TRIzol kit (MDBio Inc., Taipei, Taiwan). The reverse transcrip-
tion reaction was performed using 2 mg of total RNA that was
reverse transcribed into cDNA using an oligo(dT) primer. A
volume of 100 ng total cDNA was added per 25-ml reaction, along
with sequence-specific primers and TaqmanH probes. Sequences
for all target gene primers and probes were purchased commer-
cially (b-actin was used as the internal control) (Applied
Biosystems, CA). qPCR assays were carried out in triplicate using
a StepOnePlus sequence detection system. The cycling conditions
were 10 min of polymerase activation at 95uC, followed by 40
cycles at 95uC for 15 s and 60uC for 60 s. The threshold was set
above the non-template control background and within the linear
phase of target gene amplification to calculate the cycle number at
which the transcript was detected (denoted as CT).
Mouse xenograft models
To generate murine subcutaneous tumors, 16106 osteosarcoma
cells were injected subcutaneously to the right flanks of the nude
mice (purchased from the National Science Council Animal
Center, Taipei, Taiwan). Four weeks after injection, the subcu-
taneous tumor size had reached a tumor volume of approximately
100 mm3, and the mice then received intraperitoneal (i.p.)
injections of cisplatin (15 mg/kg) twice a week thereafter. Tumor
volumes were calculated by the following formula:
length6width26p/6. This study was carried out in strict
accordance with the recommendations in the Animal Care and
Use Guidelines of the China Medical University (Taichung,
Taiwan). The protocol was approved by the Affidavit of Approval
of Animal Use Protocol China Medical University (Permit
Number: 100-27-N). All surgery was performed under Tricholor-
oacetaldehyde Monohydrate, and all efforts were made to
minimize suffering.
Statistics
The values given are mean 6 SEM. The significance of
difference between the experimental groups and controls was
assessed by Student’s t test. The difference was considered
significant if the p value was less than 0.05.
Results
Cisplatin increases CCN2 expression in osteosarcoma
cells
Previous evidence has shown that in human squamous lung
carcinoma, 42 genes showed increases or decreases in expression
of more than 2-fold with cisplatin treatment. CCN2 is 1 of the 5
genes that showed the highest degree of variations in its
expressions [23]. Therefore, we hypothesized that CCN2 may
be involved in chemotherapy of cisplatin in human osteosarcoma
cells. First, we treated osteosarcoma cell lines (MG-63, HOS, and
U-2 OS) with cisplatin and examined CCN2 expression.
Incubation of osteosarcoma cell lines with cisplatin significantly
increased CCN2 protein and mRNA expressions in dose and time
dependent manner (Fig. 1A–D). In addition, we also found that
the protein and mRNA expression of CCN2 in primary
osteosarcoma was significantly higher than in normal osteoblasts
(Fig. 1E&F). These findings suggested that CCN2 is upregulated
during chemotherapy in osteosarcoma cells.
Overexpression of CCN2 enhances resistance to cisplatin-
promoting cell death
To examine the potential role of CCN2 on the regulation of
chemoresistance to cisplatin, we established vector expressing
control cells (MG-63/vector, HOS/vector, and U-2 OS/vector
cells) and overexpressing CCN2 cells (MG-63/CCN2, HOS/
CCN2, and U-2 OS/CCN2 cells). As shown in Figure 2A and 2B,
MG-63/CCN2, HOS/CCN2, and U-2 OS/CCN2 cells ex-
pressed higher protein and mRNA levels of CCN2 than in MG-
63/vector, HOS/vector, and U-2 OS/vector cells. Previous
studies have demonstrated that CCN2 expression confers resis-
tance to chemotherapeutic agents in glioblastoma [11] and
ovarian cancer [12]. Therefore, we hypothesized that CCN2
may promote resistance to cisplatin in human osteosarcoma cells.
Using the MTT assay, we found that overexpression of CCN2
protected cisplatin-induced cell death (Figs. 2C–E). However,
overexpression of CCN2 did not affect basal cell proliferation in
human osteosarcoma cells (Figure S1). Doxorubicin is another
chemotherapeutic agent for human osteosarcoma treatment [24].
We next examine whether CCN2 protected doxorubicin-mediated
cell death. The results also showed that CCN2 protected
doxorubicin-induced cell death in human osteosarcoma cells
(Figure S2). We next compared chemoresistance after cisplatin
stimulation between 3 osteosarcoma cell lines. We found that U-2
OS cells were more resistant than MG63 and HOS cells (Fig. 2F).
In addition, western blotting revealed a higher level of expression
of CCN2 in U-2 OS cells and a lower level in MG63 cells (Fig. 2G).
Therefore, CCN2 expression is associated with a chemoresistant
phenotype of osteosarcoma cells. To examine whether inhibition
of CCN2 reduced resistance to cisplatin, we created stable U-2 OS
cell lines expressing CCN2 short hairpin RNA (U-2 OS/CCN2
shRNA) and control short hairpin RNA (U-2 OS/Control
shRNA). Western blotting results confirmed that stable U-2 OS/
CCN2 shRNA cells significantly decreased the protein expression
of CCN2 (Fig. 2H). Using a colony formation assay, we found that
knockdown of CCN2 expression in U-2 OS cells drastically
decreased clonogenic ability upon exposure to cisplatin (Fig. 2I).
CCN2 Enhances Resistance to Cisplatin in OS
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These data suggest that CCN2 plays an important role in
increasing the resistance of osteosarcoma cells to cisplatin.
CCN2-induced resistance is mediated through inhibition
of apoptosis
Cancer therapy failure is often related to decreased sensitivity to
apoptosis in resistant tumors [25]. PARP cleavage serves as a
marker for cells undergoing apoptosis [26]. We examined PARP
expression to determine whether CCN2-induced resistance is
mediated through inhibition of apoptosis. As shown in Figure 3A,
cisplatin treatment caused strong PARP cleavage in MG-63/
vector, HOS/vector, and U-2 OS/vector cells when compared
with cells overexpressing CCN2. To further confirm that CCN2-
induced resistance is mediated through inhibition of apoptosis,
osteosarcoma cells were incubated with cisplatin, and cell
apoptosis was examined by TUNEL staining, DAPI staining, PI
staining, and caspase-3 activity assays. We found that overexpres-
sion of CCN2 significantly decreased cisplatin-mediated cell
Figure 1. The expression of CCN2 in human osteosarcoma. Cells were treated with cisplatin in different time or dose intervals, and the protein
and mRNA expression of CCN2 was examined by western blotting (A & C) and qPCR (B & D). (E & F) The protein and mRNA expression of CCN2 in
primary osteoblast cells and osteosarcoma cells were examined by western blotting and qPCR. Results are expressed as mean 6 SEM. *, p,0.05 as
compared with control group.
doi:10.1371/journal.pone.0090159.g001
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Figure 2. Overexpression of CCN2 enhances resistance to cisplatin-mediated cell death. (A & B) CCN2-overexpressing osteosarcoma cells
were established using pCDNA3.1-CCN2 vector, and protein and mRNA expression of CCN2 were examined by western blotting and qPCR. (C–F) Cells
were treated with cisplatin for 24 h, and cell viability was analyzed by MTT assay. (G) The CCN2 expression in MG-63, HOS, and U-2 OS cells was
detected by western blotting. (H) U-2 OS cells were transfected with control or CCN2 shRNA, and CCN2 expression was examined by western blotting.
(I) Cells were treated with cisplatin (4.5 mg/ml) for 24 h and then provided with fresh medium. After 1 week in culture, the colonies were stained by
crystal violet. Each experiment was done in triplicate. Results are expressed as mean 6 SEM. *, p,0.05 as compared with control group.
doi:10.1371/journal.pone.0090159.g002
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apoptosis (Fig. 3B, D, F, and H). In contrast, decreased CCN2
expression promoted cisplatin-induced apoptosis of cells in
osteosarcoma (Figs. 3C, E, G, and I). These data confirmed that
CCN2-induced resistance is mediated through inhibition of
apoptosis.
Bcl-xL and survivin are involved in CCN2-mediated
chemoresistance
Activation of the mitochondrial apoptosis pathway plays a
central role in cisplatin-induced cell death [27]. To investigate
whether mitochondrial signaling is involved in CCN2-mediated
resistance, protein expression of the Bcl-2 family was examined.
We found that overexpression of CCN2 increased Bcl-xL but not
Bcl-2, Bax, Bak, or Bad expression (Figs. 4A & B). Survivin
expression has been reported to be an indicator of poor prognosis,
low apoptotic index, poor differentiation, and high proliferation
index and might be a promising option in the treatment of
osteosarcoma [28,29,30,31]. Overexpression of CCN2 also
increased survivin expression in human osteosarcoma (Figs. 4A
& B). To further confirm whether upregulation of Bcl-xL and
survivin by CCN2 participate in the resistance to cisplatin-induced
cell apoptosis, we assessed the effects of siRNAs targeting Bcl-xL
and survivin. Protein expression of Bcl-xL or survivin was
effectively downregulated by transfection with Bcl-xL or survivin
siRNA, respectively (Fig. 4C). On the other hand, transfection of
cells with Bcl-xL or survivin siRNA reversed CCN2-mediated
chemoresistance to cisplatin-induced cell death (Figs. 4D & E).
According to these results, Bcl-xL and survivin are important
downstream effectors in CCN2-enhanced resistance from cisplat-
in-mediated cell apoptosis in osteosarcoma cells.
CCN2 activates FAK, MEK, and ERK survival signaling
pathways to subsequently protect cisplatin-induced cell
apoptosis
Resistance to cancer therapy not only decreases sensitivity to
apoptosis but also alternative pathways to promote cell survival
[25]. FAK-dependent MEK/ERK activation is a common
survival signaling pathway [16]. We found that FAK, MEK, and
ERK phosphorylation increased in MG-63-overexpressing CCN2
cells (Fig. 5A). On the other hand, overexpression of CCN2 did
not activate other survival signaling molecules, such as PI3K and
Akt (Fig. 5A). We next examined whether CCN2-mediated FAK,
MEK, and ERK activation promoted cell survival during cisplatin
treatment. Transfection of cells with FAK, MEK, and ERK
mutants or pretreatment of cells with FAK inhibitor and MEK
inhibitors (PD98059 or U0126) diminished the CCN2-mediated
chemoresistance (Figs. 5B & C). However, these inhibitors did not
affect cell viability in osteosarcoma cells (data not shown).
Therefore, CCN2 also activated FAK, MEK, and ERK survival
pathways, subsequently conveying resistance to cisplatin-induced
cell apoptosis.
CCN2 confers drug resistance to cisplatin in a mouse
xenograft model
We used a mouse xenograft model, to verify that CCN2 confers
resistance to cisplatin in vivo. Nude mice were divided into 4 groups
and inoculated with MG-63/vector, MG-63/CCN2, U-2 OS/
Control shRNA, or U-2 OS/CCN2 shRNA cells, respectively. As
tumors reached 100 mm3 in size, mice were treated with cisplatin.
As shown in Figures 6A–C, overexpression of CCN2 in MG-63
cells promoted resistance to cisplatin. On the other hand,
knockdown of CCN2 in U-2 OS cells increased the therapeutic
effect of cisplatin. Finally, ex vivo analysis of tumors excised from
mice showed significantly increasing CCN2, Bcl-xL, and survivin
expression in the CCN2-overexpressing group compared to that of
the control group, as shown by western blotting (Fig. 6D).
However, knockdown of CCN2 had contrasting effects (Fig. 6D).
These data provide in vivo evidence to support CCN2 as a potential
oncogene that renders anti-chemotherapy effect of human
osteosarcoma.
Discussion
An increasing number of osteosarcoma patients develop
resistance to chemotherapy drugs, with potential resistance
mechanisms that include dysfunctional membrane transport,
resistance to apoptosis, and the persistence of stem cell-like tumor
cells [2,32]. Here, we show that overexpressing CCN2 in human
osteosarcoma cells enhanced resistance to cisplatin through
inhibiting cisplatin-induced apoptosis and promoting tumor cell
survival. CCN2 overexpression resulted in specific upregulation of
Bcl-xL and survivin. CCN2 also activated FAK, MEK, and ERK
survival signaling pathways to enhance cell survival during
cisplatin treatment. Taken together, we suggest that CCN2 plays
an important role in osteosarcoma progression by supporting
tumor cell survival and drug resistance. To examine whether
CCN2 protected chemoresistance is a general phenomenon, the
prostate (PC3), lung (A549), and gastric (AGS) cancer cells were
used. Overexpression of CCN2 protected cisplatin- or doxorubi-
cin-mediated cell death in these cancer cells (Figure S3).
Therefore, CCN2 protect chemoresistance is a general phenom-
enon in human cancer cells.
CCN2 plays important roles in many biological processes,
including cell adhesion, migration, proliferation, angiogenesis,
skeletal development, and tissue wound repair. CCN2 is also
critically involved in several forms of cancers [11,12,13], although
there is dispute about the role of CCN2 in tumor carcinogenesis
and its association with malignancy. For example, in human
rhabdomyosarcoma, CCN2 has been demonstrated to be a useful
therapeutic agent and disrupting CCN2 expression using CCN2-
neutralizing antibodies can enhance apoptosis and inhibit
angiogenesis [33]. In human lung adenocarcinoma, CCN2
inhibits metastasis and invasion by a CRMP-1-dependent
mechanism [34]. CCN2 also inhibits cell growth in squamous
cell carcinoma [35]. Additionally, CCN2 presence has been shown
to be a survival factor [36]. In colorectal cancer, patients showed
better overall survival when tumors displayed higher CCN2
expression. Alterations to the protein level of CCN2 in colorectal
cancer cell lines also negatively modulated their invasive ability
[37]. In breast cancer, CCN2 expression confers resistance to
chemotherapeutic agents through augmenting a survival pathway
[38]. However, the effect of CCN2 in human osteosarcoma is
largely unknown. In the current study, we found that cisplatin
increased osteosarcoma cell death through an apoptotic mecha-
nism, using TUNEL staining, DAPI staining, and cell cycle
Figure 3. CCN2-induced resistance is mediated through inhibition of apoptosis. (A) Cells were treated with cisplatin for indicated
concentration for 24 h, and PARP expression was examined by western blotting. (B–G) Cells were treated with cisplatin (4.5 mg/ml) for 24 h, and cell
apoptosis was examined by TUNEL analysis (B & C), DAPI assay (D & E), PI staining (F & G), and caspase-3 activity (H & I). Each experiment was done in
triplicate. Results are expressed as mean 6 SEM. *, p,0.05 as compared with control group.
doi:10.1371/journal.pone.0090159.g003
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analysis. In addition, overexpression of CCN2 increased the
resistance to cisplatin-mediated cell apoptosis. To the best of our
knowledge, this study provided the first evidence that CCN2
provides enhanced chemoresistance to cisplatin in human
osteosarcoma. Therefore, CCN2 may be a novel chemotherapy
target in human osteosarcoma.
Most of the pro- and anti-apoptotic members of the Bcl-2
protein family have been shown to modulate the response to
cisplatin. In some cancers, including head and neck cancer,
ovarian cancer, breast cancer, and non-small-cell lung carcinoma
(NSCLC), the Bcl-2 family of proteins correlates to cisplatin
resistance and tumor recurrence [39]. Inhibition of Bcl-xL
Figure 4. Bcl-xL and survivin are involved in CCN2-mediated chemoresistance. (A) Protein expression of the Bcl-2 family was examined by
western blotting. (B) Cells were treated with cisplatin (4.5 mg/ml) for 24 h, and the mRNA expression of Bcl-xL and survivin was examined by qPCR. (C)
Cells were transfected with control, Bcl-xL, or survivin siRNA, and the protein expression was examined by western blotting. (D & E) Cells were
transfected with control, Bcl-xL, or survivin siRNA, and cell viability and apoptosis was analyzed by MTT assay and PI staining. Each experiment was
done in triplicate. Results are expressed as mean 6 SEM. *, p,0.05 as compared with MG-63/vector group; # P,0.05 compared with MG-63/CCN2
cisplatin-treated control group.
doi:10.1371/journal.pone.0090159.g004
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expression is essential for therapeutic apoptosis and enhanced
chemosensitivity in osteosarcoma cancer cells [40]. Here, we found
that CCN2 increased Bcl-xL but not Bcl-2, Bax, Bak, and Bad
expression. Bcl-xL siRNA diminished CCN2-mediated chemore-
sistance to cisplatin. Therefore, Bcl-xL is the most important
effector in CCN2-mediated chemoresistance of the Bcl-2 family. On
the other hand, increased levels of survivin have been found in
gastric, esophageal, ovarian cancer, and NSCLC patients [41];
deregulation of survivin expression in various cancer types leads to
increased cisplatin-resistance in patients and is associated with a
negative prognosis [42]. In this study, we used specific siRNAs
against survivin, which significantly abolished cisplatin-induced
CCN2-mediated resistance to apoptosis. We strongly believe that
survivin is a critical factor for human osteosarcoma therapy.
Cisplatin induces apoptosis of cancer cells, which usually raise the
defects in apoptotic programs to provide resistance to apoptosis, and
Bcl-xL and survivin are important mediators during this process.
Cancer treatments can fail because cancer cells enhance some
chemical signals, by rapidly developing ways to interact with the
supportive ECM. CCN2 can be ECM-associated through
interactions with specific integrins, and the binding of CCN2 to
integrins could activate intracellular pathways, such as cell
adhesion, migration, and ECM protein deposition [43]. FAK is
a potential signaling molecule that mediates the activation of
integrin-mediated signaling. MEK and ERK are often upregu-
lated in response to DNA-damaging chemotherapeutic agents,
such as cisplatin [44]. In the current study, we found that CCN2
increased FAK, MEK, and ERK activation. However, CCN2 did
not affect phosphorylation of PI3K and the Akt signaling cascade.
Furthermore, FAK and MEK inhibitors reversed CCN2-mediated
resistance to cisplatin. This was confirmed by the observation that
FAK, MEK, and ERK mutants prevented the enhancement of
chemoresistance in human osteosarcoma cells. We suggested that
CCN2 increased FAK, MEK, and ERK survival signaling
Figure 5. CCN2 activates FAK, MEK, and ERK survival signaling pathways during chemoresistance. (A) Protein expression was examined
by western blotting. (B & C) Cells were transfected with FAK, MEK, and ERK mutants or pretreated with FAK inhibitor (10 mM), PD98059 (10 mM), and
U0126 (10 mM), followed by stimulation with cisplatin for 24 h. Cell survival ability and apoptosis were examined by MTT assay and PI staining. Each
experiment was done in triplicate. Results are expressed as mean6 SEM. *, p,0.05 as compared with MG-63/vector group; # P,0.05 compared with
MG-63/CCN2 cisplatin-treated control group.
doi:10.1371/journal.pone.0090159.g005
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pathways and subsequently protected cisplatin-induced cell
apoptosis in human osteosarcoma.
In conclusion, we showed that cisplatin-induced CCN2 expression
in osteosarcoma cells promoted cell survival ability, which inhibited
apoptosis and increased resistance from cisplatin treatment. Our in
vitro and in vivo xenograft studies showed that overexpressing CCN2
significantly increased tumor cell survival, and suppression of CCN2
expression significantly increased drug sensitivity of osteosarcoma
cells. Thus, we conclude that CCN2 might be a critical oncogene
and believe these data support an investigation of CCN2 as a
strategic target for osteosarcoma therapy.
Supporting Information
Figure S1 The cell proliferation rate of MG-63/vector
and MG-63/CCN2 cells. Cells were harvested in 0, 2, 4, and 8
days. The proliferation was examined by MTT assay. Each
experiment was done in triplicate.
(TIF)
Figure S2 Overexpression of CCN2 enhances resistance
to doxorubicin-mediated cell death. Cells were treated with
doxorubicin for 24 h, and cell viability was analyzed by MTT
assay. Each experiment was done in triplicate.
(TIF)
Figure S3 Overexpression of CCN2 enhances resistance
to cisplatin- and doxorubicin-mediated cell death. Cells
were treated with cisplatin or doxorubicin for 24 h, and cell
viability was analyzed by MTT assay. Each experiment was done
in triplicate.
(TIF)
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